Lyphe Dispensary has unveiled an extended Noidecs V collection, an affordable and premium-quality medical cannabis line, developed in response to patient needs.
After the success of Noidecs Vital Platinum OG, introduced in June 2024, the new range features four products: VOne, VTwo, VThree, and VFour. These full-flower cannabis options offer patients a straightforward choice tailored to their needs.
Designed for new and experienced users alike, VOne has the lowest THC level for gentle relief, while VFour provides the highest concentration, ensuring a solution for every patient—all at an affordable price.
“Patients are advocating for lower cost, yet sustainable options, and we want them to know that Lyphe is not only listening but taking action,” said Hayley Thompson, Managing Director at Lyphe Clinic. “The Noidecs VOne-VFour line aims to bridge the gap between quality and cost, offering patients a reliable and accessible option for managing their health conditions.”
The Noidecs V collection is a testament to Lyphe’s commitment to balancing cost with quality, supported by efficient supply chains and economies of scale.
With MHRA regulatory changes impacting the branding of “Vital,” the line will evolve in name but not in concept.
Noidecs VThree launches in Winter 2024, with the complete range available early in 2025. Announcements on launch dates are forthcoming.
